Synthetic BPC-157, a pentadecapeptide comprising 15 amino acids isolated from the much larger BPC protein, has been found to retain many of the healing properties of its parent molecule
brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetryzoline, tramazoline, xylometazoline) and those stimulants included in the 2026 Monitoring Program* * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2026 Monitoring Program and are not considered Prohibited Substances
The amount you add determines the concentration, which determines how many units to draw for each dose
In Achilles tendon transection models in rats, systemic BPC-157 administration via intraperitoneal injection produced significantly improved recovery compared to controls
This head-to-head comparison examines both peptide injections through the lens of clinical evidence, mechanism of action, safety data, and real-world availability in 2026